Objectives: We investigated whether an active blood pressure-lowering strategy is associated with more patients receiving thrombolytics compared with a conservative "watch and measure" strategy, and assessed safety and functional outcome of these 2 treatment strategies. Methods: This is a post hoc analysis in 2 randomized controlled stroke trials, the PRACTISE (Promoting Acute Thrombolysis in Ischemic Stroke) and the PASS (Preventive Antibiotics in Stroke Study). We included all patients with elevated pretreatment blood pressure above 185/110 mm Hg at presentation but otherwise eligible for IV thrombolysis (IVT). The decision to use an active or conservative strategy was in accordance with local hospital treatment guidelines. The primary ou...
BACKGROUND: Blood pressure (BP) lowering in people who have had a stroke or transient ischaemic atta...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic tre...
Objectives: We investigated whether an active blood pressure-lowering strategy is associated with mo...
Background: Intravenous thrombolysis (IVT) with (recombinant) tissue plasminogen activator is an eff...
BACKGROUND: Intravenous thrombolysis (IVT) with (recombinant) tissue plasminogen activator is an eff...
Background: Intravenous thrombolysis (IVT) with (recombinant) tissue plasminogen activator is an eff...
Introduction: The purpose of this study was to assess safety and efficacy of thrombolysis in the set...
Background and Purpose: The optimal management of blood pressure (BP) in acute stroke remains unclea...
Background and purpose: Most guidelines for intravenous thrombolysis (IVT) in acute ischaemic stroke...
Background and Purpose: From small pilot studies, uncontrolled pretreatment systolic blood pressure ...
International audienceBACKGROUND: High systolic blood pressure after successful endovascular therapy...
Background: One quarter to one third of patients eligible for systemic thrombolysis are on antiplate...
Background: Stroke is a leading cause of death and disability internationally. One of the three effe...
Objective: Limited data exist on the optimum level of SBP in thrombolyzed patients with acute ischem...
BACKGROUND: Blood pressure (BP) lowering in people who have had a stroke or transient ischaemic atta...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic tre...
Objectives: We investigated whether an active blood pressure-lowering strategy is associated with mo...
Background: Intravenous thrombolysis (IVT) with (recombinant) tissue plasminogen activator is an eff...
BACKGROUND: Intravenous thrombolysis (IVT) with (recombinant) tissue plasminogen activator is an eff...
Background: Intravenous thrombolysis (IVT) with (recombinant) tissue plasminogen activator is an eff...
Introduction: The purpose of this study was to assess safety and efficacy of thrombolysis in the set...
Background and Purpose: The optimal management of blood pressure (BP) in acute stroke remains unclea...
Background and purpose: Most guidelines for intravenous thrombolysis (IVT) in acute ischaemic stroke...
Background and Purpose: From small pilot studies, uncontrolled pretreatment systolic blood pressure ...
International audienceBACKGROUND: High systolic blood pressure after successful endovascular therapy...
Background: One quarter to one third of patients eligible for systemic thrombolysis are on antiplate...
Background: Stroke is a leading cause of death and disability internationally. One of the three effe...
Objective: Limited data exist on the optimum level of SBP in thrombolyzed patients with acute ischem...
BACKGROUND: Blood pressure (BP) lowering in people who have had a stroke or transient ischaemic atta...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic tre...